Methylation of Tumor Suppressor Genes in a Novel Panel Predicts Clinical Outcome in Paraffin-embedded Bladder Tumors

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Mar 1

PMID 24577895

Citations 15

Authors

Rodrigo Garcia-Baquero

Patricia Puerta

Manuel Beltran

Miguel Alvarez-Mujica

Jose Luis Alvarez-Ossorio

Marta Sanchez-Carbayo

Affiliations

Soon will be listed here.

Abstract

DNA methylation of tumor suppressor genes (TSGs) represents a frequent and early epigenetic event with potential applications for cancer detection and disease evolution. Our aim was to examine the stratification and prognostic biomarker role of the methylation of a novel panel of TSGs in bladder cancer. The methylation status of 18 TSGs was evaluated in bladder cancer cells (n=14) and paraffin-embedded primary bladder tumors (n=61), using a methylation-specific multiplex ligation-dependent probe amplification assay (MS-MLPA). Recurrence, progression, and disease-specific survival were analyzed using univariate and multivariate Cox models. PRDM2, HLTF, ID4, DLC1, BNIP3, H2AFX, CACNA1G, TGIF, and CACNA1A were discovered methylated in bladder cancer. The methylation of RUNX3 (p=0.026), TWIST1 (p=0.009), SFRP4 (p=0.002), and CCND2 (p=0.027) correlated to tumor stage. Univariate analyses indicated prognostic associations for recurrence (DLC1, SFRP5, H2AFX, CACNA1G), progression (DLC1, SFRP5, CACNA1G), disease-specific (PRDM2, DLC1, SFRP5, CACNA1G, and TIMP3), and overall survival (SFRP5 and TIMP3). In multivariate analyses, several TSGs remained as independent prognosticators for recurrence (SFRP5, H2AFX), progression (CACNA1G), and disease-specific survival (SFRP5). Thus, a novel set of TSGs was identified, frequently methylated in bladder cancer cells and tumors. TSG methylation allowed histopathologic and outcome stratification using paraffin-embedded tumors. This is clinically relevant by offering a strategy for the management of patients affected with uroepithelial neoplasias in pathology routine laboratories.

Citing Articles

Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).

Crabb S, Danson S, Catto J, Hussain S, Chan D, Dunkley D Clin Cancer Res. 2021; 27(7):1882-1892.

PMID: 33472913 PMC: 7611191. DOI: 10.1158/1078-0432.CCR-20-3946.

DNA Methylation as a Therapeutic Target for Bladder Cancer.

Nunes S, Henrique R, Jeronimo C, Paramio J Cells. 2020; 9(8).

PMID: 32784599 PMC: 7463638. DOI: 10.3390/cells9081850.

ID4 Promotes Breast Cancer Chemotherapy Resistance via CBF1-MRP1 Pathway.

Zhang X, Gu G, Song L, Wang D, Xu Y, Yang S J Cancer. 2020; 11(13):3846-3857.

PMID: 32328189 PMC: 7171490. DOI: 10.7150/jca.31988.

Genomic Subtyping in Bladder Cancer.

Jalanko T, de Jong J, Gibb E, Seiler R, Black P Curr Urol Rep. 2020; 21(2):9.

PMID: 32166460 DOI: 10.1007/s11934-020-0960-y.

Co-occurrence and Mutual Exclusivity Analysis of DNA Methylation Reveals Distinct Subtypes in Multiple Cancers.

Ding W, Feng G, Hu Y, Chen G, Shi T Front Cell Dev Biol. 2020; 8:20.

PMID: 32064261 PMC: 7000380. DOI: 10.3389/fcell.2020.00020.

References

Nygren A, Ameziane N, Duarte H, Vijzelaar R, Waisfisz Q, Hess C . Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005; 33(14):e128. PMC: 1187824. DOI: 10.1093/nar/gni127. View

Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H . Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006; 12(7 Pt 1):2109-16. DOI: 10.1158/1078-0432.CCR-05-2468. View

Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S, Shivapurkar N . Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer. 2004; 113(4):600-4. DOI: 10.1002/ijc.20622. View

Sanchez-Carbayo M . Urine epigenomics: a promising path for bladder cancer diagnostics. Expert Rev Mol Diagn. 2012; 12(5):429-32. DOI: 10.1586/erm.12.42. View

Zuiverloon T, Beukers W, van der Keur K, Munoz J, Bangma C, Lingsma H . A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 2011; 109(6):941-8. DOI: 10.1111/j.1464-410X.2011.10428.x. View

Pu R, Laitala L, Clark D . Methylation profiling of urothelial carcinoma in bladder biopsy and urine. Acta Cytol. 2006; 50(5):499-506. DOI: 10.1159/000326003. View

Cabello M, Grau L, Franco N, Orenes E, Alvarez M, Blanca A . Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J Mol Diagn. 2011; 13(1):29-40. PMC: 3070573. DOI: 10.1016/j.jmoldx.2010.11.008. View

Friedrich M, Chandrasoma S, Siegmund K, Weisenberger D, Cheng J, Toma M . Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer. 2005; 41(17):2769-78. DOI: 10.1016/j.ejca.2005.07.019. View

Kim W, Kim E, Jeong P, Quan C, Kim J, Li Q . RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 2005; 65(20):9347-54. DOI: 10.1158/0008-5472.CAN-05-1647. View

10.

Wiklund E, Bramsen J, Hulf T, Dyrskjot L, Ramanathan R, Hansen T . Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2010; 128(6):1327-34. DOI: 10.1002/ijc.25461. View

11.

Esteller M . CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002; 21(35):5427-40. DOI: 10.1038/sj.onc.1205600. View

12.

Hoque M, Begum S, Brait M, Jeronimo C, Zahurak M, Ostrow K . Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J Urol. 2007; 179(2):743-7. PMC: 2674621. DOI: 10.1016/j.juro.2007.09.019. View

13.

Sanchez-Carbayo M . Hypermethylation in bladder cancer: biological pathways and translational applications. Tumour Biol. 2012; 33(2):347-61. DOI: 10.1007/s13277-011-0310-2. View

14.

Marsit C, Karagas M, Andrew A, Liu M, Danaee H, Schned A . Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 2005; 65(16):7081-5. DOI: 10.1158/0008-5472.CAN-05-0267. View

15.

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

16.

Brait M, Begum S, Carvalho A, Dasgupta S, Vettore A, Czerniak B . Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17(10):2786-94. PMC: 2778751. DOI: 10.1158/1055-9965.EPI-08-0192. View

17.

Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin T . Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer. 2007; 98(2):466-73. PMC: 2361432. DOI: 10.1038/sj.bjc.6604143. View

18.

Jarmalaite S, Andrekute R, Scesnaite A, Suziedelis K, Husgafvel-Pursiainen K, Jankevicius F . Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study. J Cancer Res Clin Oncol. 2009; 136(6):847-54. DOI: 10.1007/s00432-009-0725-y. View

19.

Agundez M, Grau L, Palou J, Algaba F, Villavicencio H, Sanchez-Carbayo M . Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol. 2011; 60(1):131-40. DOI: 10.1016/j.eururo.2011.04.020. View

20.

Wolff E, Liang G, Jones P . Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol. 2006; 2(10):502-10. DOI: 10.1038/ncpuro0318. View